AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05060185 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: the Flow Diverter
Description: Those who meet the inclusion criteria but do not meet the exclusion criteria will be enrolled through the electronic central registration system. The investigator log in to the central registration system, fill in the subject information and submit it who enroll in the study. The investigator complete the surgery and conduct relevant evaluation according to the protocol.
Study NCT06253975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adipose tissue derived extracellular vesicles (AT-EVs)
Description: Extracellular vesicles from patient's adipose tissue together with HA
Study NCT06582628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide capsule
Description: Enzalutamide capsules 160 mg orally daily
Study NCT06582628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide capsule and Talazoparib capsule
Description: Enzalutamide capsules 160 mg plus talazoparib capsules 0.5 mg, both orally daily
Study NCT05020795 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Description: Clot retrieval for large vessel occlusion in acute ischaemic stroke
Study NCT05020795 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular thrombectomy
Description: Clot retrieval for large vessel occlusion in acute ischaemic stroke
Study NCT04821544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (with a focus on self-compassion; MBSC)
Description: 8-week MBSC intervention with a focus on increasing self-compassion
Study NCT04821544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D at 2,000 IU/day for 8 weeks.
Study NCT06253975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyaluronic acid
Description: Use HA only as a placebo
Study NCT05570383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dust mite drops (trade name: Changdi, Zhejiang Tawu Biotechnology Co. Ltd.).
Description: The experimental group will be with Sublingual immunotherapy (trade name: Changdi, Zhejiang Tawu Biotechnology Co., Ltd.). The control group will be with Mometasone Furoate Aqueous Nasal Spray (NASUNA); The treatment course of the two groups will be 3 months.
Study NCT05570383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dust mite drops (trade name: Changdi, Zhejiang Tawu Biotechnology Co. Ltd.).
Description: The experimental group will be with Sublingual immunotherapy (trade name: Changdi, Zhejiang Tawu Biotechnology Co., Ltd.). The control group will be with Mometasone Furoate Aqueous Nasal Spray (NASUNA); The treatment course of the two groups will be 3 months.
Study NCT06318234 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-FAPI，18F-FDG
Description: FAPI and FDG combined with PET/MR imaging in patients with rectal cancer after neoadjuvant therapy
Study NCT03660917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole
Description: Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months in the treated group.
Study NCT03660917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months in the treated group.
Study NCT03660917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug for 6 months, however they will receive riluzole during the last 6 months of study, so that all patients will undergo the active drug in the last phase of the study.
Study NCT06041893 — intervention group
Intervention type: DRUG
Intervention: ATG-LDPTCy
Description: antithymocyte globulin with low dose post-transplant cyclophosphamide
Study NCT04738487 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Vibostolimab
Description: Coformulation of pembrolizumab (MK-3475) 200mg and vibostolimab (MK-7684) 200mg. Participants receive the coformulation by intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years).
Study NCT04738487 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Participants receive 200 mg of pembrolizumab by intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years).
Study NCT05171543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periapical surgery with placement of an allograft and a membrane
Description: Periapical surgery will be done followed by placement of an allograft into the defect and a membrane over the defect before closure of the flap.
Study NCT04902131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mL
Description: Single dose cross-over bioequivalence trial
Study NCT04902131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A MENOPUR powder including solvent for solution for injection, 75 IU
Description: Single dose cross-over bioequivalence trial
Study NCT06242600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drainage of the bladder by indwelling Foley catheter
Description: Drainage of the bladder by transurethral catheterization with an indwelling Foley catheter of patients undergoing a TUR-B procedure and in need of a Foley catheter for up to 24 hrs.
Study NCT06242600 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Drainage of the bladder by indwelling Foley catheter
Description: Drainage of the bladder by transurethral catheterization with an indwelling Foley catheter of patients undergoing a TUR-B procedure and in need of a Foley catheter for up to 24 hrs.
Study NCT06402643 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pterygium Excision
Description: Pterygium will be surgically removed utilizing conventional resection techniques, entailing a blunt resection of the head, neck, and body of the pterygium. Subsequent to the resection, the surgical site will be polished using a surgical diamond burr if deemed necessary, and hemostasis will be achieved using bipolar cautery.
Study NCT06402643 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pterygium Excision
Description: Pterygium will be surgically removed utilizing conventional resection techniques, entailing a blunt resection of the head, neck, and body of the pterygium. Subsequent to the resection, the surgical site will be polished using a surgical diamond burr if deemed necessary, and hemostasis will be achieved using bipolar cautery.
Study NCT05931484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemfibrozil
Description: Oral Solution
Study NCT05931484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dose of Placebo
Study NCT05222269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PTF
Description: 68Ga-PTF will be injected intravenously at three time points during the course of the standard treatment of the patient.
Study NCT04807517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: All participants in the study will receive open-label treatment with orally administered buspirone for the full duration of the 16-week trial. Buspirone has high affinity for serotonin 5-HT1A and 5-HT2 receptors and moderate affinity for dopamine D2 receptors. It is approved for the management of generalized anxiety disorder in adults.
Study NCT05568407 — intervention group
Intervention type: DRUG
Intervention: Avelumab
Description: As used in real world practice
Study NCT06630962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Navigation Program
Description: A salaried financial navigator will be hired by the study sites. All responsibilities of the navigator will revolve around the structured financial navigation program. There is currently no research indicating that such a role has been incorporated at cancer centers in sub-Saharan Africa.~Through this program, the financial navigator will educate participants on financial literacy, insurance plans and payment options available through charities and financial assistance programs. In addition to providing financial counseling, the financial navigator will verify participant insurance documents, maintain records of financial agreements, and coordinate payments with insurance companies.
Study NCT06629376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Recombinant Candida Utilis Uricase for Injection
Description: According to the dosage requirements of each experimental group, intravenous infusion should be administered for at least 2 hours each time
Study NCT06176040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAVO101
Description: TAVO101 IV Infusion.
Study NCT06629376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated Recombinant Candida Utilis Uricase for Injection
Description: According to the dosage requirements of each experimental group, intravenous infusion should be administered for at least 2 hours each time
Study NCT05538754 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EVO ICL
Description: The EVO ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.
Study NCT05926271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: See arm description earlier.
Study NCT05926960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encorafenib
Description: encorafenib
Study NCT05926960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: binimetinib
Study NCT05926960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: pembrolizumab
Study NCT05926960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ipilimumab
Description: ipilimumab
Study NCT05926960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nivolumab
Description: nivolumab
Study NCT05030311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064 25 mg (b.i.d)
Description: LOU064 25 mg was administered by oral route twice a day (b.i.d) as a tablet.
Study NCT05030311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05030311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064 25 mg (b.i.d) as a tablet.
Description: LOU064 25 mg was administered by oral route twice a day (b.i.d) as a tablet in open label phase.
Study NCT05030311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LOU064 25 mg (b.i.d) as a tablet.
Description: LOU064 25 mg was administered by oral route twice a day (b.i.d) as a tablet in open label phase.
Study NCT06153693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily (QD) for 12 weeks
Study NCT06153693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorundrostat Dose 1
Description: 50 mg lorundrostat Dose 1 once daily (QD) for 12 weeks
Study NCT06153693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorundrostat Dose 2
Description: 50 mg lorundrostat Dose 1 once daily (QD) for 6 weeks then 100 mg lorundrostat Dose 2 once daily (QD) for 6 weeks for subjects who meet prespecified criteria
Study NCT06121843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986393
Description: Specified dose on specified days
Study NCT06121843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alnuctamab
Description: Specified dose on specified days
Study NCT06121843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezigdomide
Description: Specified dose on specified days
Study NCT06121843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Specified dose on specified days
Study NCT05192057 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline inhalation
Description: Hypertonic Saline inhalation is thought to increase mucociliary clearance of the airways
Study NCT05786066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel 6 MG
Description: Perampanel will be administered 2.5 hours before Ketamine infusion
Study NCT05786066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine infusion (0.5 mg/kg infusion over 40 minutes) will be administered 2.5 hours post perampanel or placebo administration.
Study NCT05786066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Ketamine infusion (0.5 mg/kg infusion over 40 minutes) will be administered 2.5 hours post perampanel or placebo administration.
Study NCT05786066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered 2.5 hours before Ketamine infusion
Study NCT05192096 — intervention group
Intervention type: BEHAVIORAL
Intervention: Train-the-trainer workshop
Description: To deliver health-related information to trainees, which facilitate improving their knowledge, confidence, and ability to share and discuss health-related information with others, including service users, families and friends.
Study NCT02832531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg)
Description: Rivaroxaban is superior to aspirin for the prevention of the composite of stroke or systemic embolism in patients with RVHD with AF or flutter who are unsuitable for VKA therapy, or in patients with RVHD without AF or Flutter with at least one of the following:~1. Left atrial enlargement ≥ 5.5 cm, OR~2. Left atrial spontaneous echo contrast OR~3. Left atrial thrombus OR~4. Frequent ectopic atrial activity (>1000/24 hours) on Holter ECG.
Study NCT02832531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Rivaroxaban is superior to aspirin for the prevention of the composite of stroke or systemic embolism in patients with RVHD with AF or flutter who are unsuitable for VKA therapy, or in patients with RVHD without AF or Flutter with at least one of the following:~1. Left atrial enlargement ≥ 5.5 cm, OR~2. Left atrial spontaneous echo contrast OR~3. Left atrial thrombus OR~4. Frequent ectopic atrial activity (>1000/24 hours) on Holter ECG.
Study NCT05750160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy
Description: Music therapy that have been made by Music Therapist after Focus Group discussion, given three times a week for 4 weeks
Study NCT05639114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ianalumab
Description: ianalumab s.c. monthly or quarterly
Study NCT06569979 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: The survey was developed using the Google Forms platform. The first part of the questionnaire consisted of descriptive information such as age, gender, duration of academic experience. In addition to this informations, the questionnaire also included information related the status of use ICF in any fields.~In the other part of the questionnaire, a total of 59 questions (16 related to body functions, 3 related to body structures, 30 related to activity and participation, 10 related to environmental factors) were asked to the academicians whether these categories are present in the amputee rehabilitation course content. Academicians were asked to answer yes or no to each question.
Study NCT06569888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIPUS stimulation
Description: Low Intensity Pulsed Ultrasound stimulation of the gut at the pre-clinically optimized conditions and energy dosage
Study NCT06570564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The arm crank ergometer
Description: Before starting the program, patients will perform an adaptation session for familiarization with the ergometer and also to identify the training load. For this, patients will perform 10 bouts of two minutes of exercising with a minimum load and two minute passive intervals between bouts. Patients will be instructed to maintain 50 revolutions per minute (RPM) during the exercise. Subsequently, to determine the training load for each session, patients will perform a progressive test where the load will be increased by 10 watts every minute of the test, following the protocol of two minutes of exercise with two minutes of interval
Study NCT06570564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bicycle ergometer
Description: bicycle ergometer program will consist of a bicycling exercise 3 days per week. Exercise intensity was set at 70% of maximal load with 30 minutes per session. The exercise protocol also incorporated warm-up and cool-down sessions that involved stretches of the major lower limb muscle groups (total exercise time, 40-60 minutes)
Study NCT06570564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treadmill
Description: Supervised treadmill exercise as routine physiotherapy program
Study NCT06258512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention with a narrative approach.
Description: Health social workers will carry out a intervention with a narrative approach, through its training profile based on transversal skills, which will consist of 10 sessions carried out over five months. The interval between sessions will be of two weeks with a specific duration of fifty minutes per session. This type of intervention, with the objective of reorienting and redefining the demand or the initial problems that motivated the consultation, gives space to the patient\&#39;s subjective complaint, as well as to locate the understanding of the discomfort and the symbolic meaning of the symptoms.~That is, recognizing the physical symptoms while listening to stories of chaos to legitimize both the user and his symptoms, an encounter that allows return the user to its context without feeling rejected or judged by the health system.
Study NCT05639114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo s.c. monthly
Study NCT06569797 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oligosaccharides and multiple nutrients
Description: The effect of adding milk oligosaccharides and optimizing multiple nutrients to infant formula on the growth and development of infants aged 0-1 years
Study NCT06569797 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: no oligosaccharides and optimizing multiple nutrients
Description: The effect of traditional infant formula milk powder optimized without adding milk oligosaccharides and multiple nutrients on the growth and development of infants aged 0-1 years old.
Study NCT06569797 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: breastfeeding
Description: The impact of breastfeeding on the growth and development of infants aged 0-1 years old.
Study NCT05906589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: The participant will take inulin twice daily over a 14 day period.
Study NCT05906589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium
Description: The participant will take psyllium twice daily over a 14 day period.
Study NCT05906589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: The participant will take maltodextrin twice daily over a 14 day period.
Study NCT05398848 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant two-component COVID-19 vaccine (CHO cell)
Description: Before reconstitution: Lyophilized powder for reconstitution in single-use vials After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter
Study NCT05398848 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Before reconstitution:~Lyophilized powder for reconstitution in single-use vials~After reconstitution with BFA03 adjuvant:~Milk-white solution with no visible foreign matter
Study NCT06261060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given by PO
Study NCT04743856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ActiveGOALSv2
Description: 13 weekly self-guided sessions on problem solving and goal setting related to increasing physical activity, and weekly remote coaching support. Once a month support materials sent monthly from months 4-12 of intervention.
Study NCT04781972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: single dose of 10 mg or 15 mg
Study NCT04781972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate
Description: single dose of 10 mg or 15 mg
Study NCT04781972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study NCT04781972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT05050279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib capsule
Description: oral capsule
Study NCT05050279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: oral capsule
Study NCT06409286 — intervention group
Intervention type: DEVICE
Intervention: Thermal Anisotropy Measurement Device
Description: A wireless device for non-invasively assessing CSF shunt flow
Study NCT04578041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRPMS (Transcranial Rotating Permanent Magnet Stimulation)
Description: TRPMS ( is administered through a head cap worn by the participant and controlled by QHTimeStimulate application via computer tablet.~* Modality: Excitatory stimulation~* Frequency: 5 Hz~* Interval between stimulus: 100 ms~* Duration of each stimulus: 25 ms~* Duration of stimulation: 40 minutes~* Position of microstimulators: over primary motor cortex and supplementary motor area for Arm 1; over left and right dorsolateral prefrontal cortex for Arm 2